A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Chłoniak grudkowy potwierdzony badaniem, nieleczony wcześniej.
- •Chłoniak określonego typu (klasyczny chłoniak grudkowy CD19+ i CD20+).
- •Chłoniak w zaawansowanym stadium (od II do IV wg Ann Arbor).
- •Wskaźnik ryzyka FLIPI od 2 do 5.
- •Widoczny w badaniach obrazowych (np. tomografii).
- •Posiadanie próbki tkanki guza do badania (np. z biopsji).
- •Jeśli pacjent jest nosicielem wirusa HIV, musi mieć dobrze kontrolowane HIV.
- •Jeśli pacjent jest nosicielem wirusa zapalenia wątroby typu B, musi mieć niewykrywalną ilość wirusa i być leczony.
✗ Disqualifies
- •Wcześniejsze leczenie chłoniaka grudkowego chemioterapią lub radioterapią.
- •Inny typ chłoniaka grudkowego niż klasyczny lub chłoniak o szybszym przebiegu.
- •Znane problemy z centralnym układem nerwowym.
- •Przeszłe lub obecne poważne choroby serca i naczyń mózgowych.
- •Szczególne problemy związane z HIV, takie jak mięsak Kaposiego.
- •Otrzymanie żywej szczepionki w ciągu ostatnich 30 dni.
- •Choroby autoimmunologiczne wymagające leczenia w ciągu ostatnich 2 lat.
- •Aktywne infekcje wymagające leczenia ogólnego.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (33)
City of Hope - Duarte Cancer Center ( Site 1301)
Duarte, United States
University of Kentucky ( Site 1303)
Lexington, United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 1311)
Hackensack, United States
Duke Cancer Center Clinic 1B/C Onc/Heme ( Site 1307)
Durham, United States
SCRI Oncology Partners ( Site 7000)
Nashville, United States
Instituto Alexander Fleming ( Site 0105)
Ciudad Autonoma de Buenos Aires, Argentina
Hospital Aleman ( Site 0101)
Buenos Aires, Argentina
Sanatorio Nuestra Senora del Rosario ( Site 0104)
Rosario, Argentina
Hospital Privado Universitario de Córdoba ( Site 0102)
Córdoba, Argentina
Box Hill Hospital ( Site 0201)
Box Hill, Australia
Biocenter ( Site 0402)
Concepción, Chile
Fundacion Arturo Lopez Perez FALP ( Site 0404)
Santiago, Chile
Beijing Cancer hospital ( Site 0501)
Beijing, China
Fudan University Shanghai Cancer Center ( Site 0504)
Shanghai, China
Evangelismos General Hospital of Athens ( Site 1501)
Athens, Greece
General Hospital of Athens "Laiko" ( Site 1502)
Athens, Greece
Hadassah Medical Center ( Site 0701)
Jerusalem, Israel
Sheba Medical Center ( Site 0702)
Ramat Gan, Israel
Sourasky Medical Center ( Site 0704)
Tel Aviv, Israel
INOC - Istituto Nazionale Oncologico Candiolo ( Site 1602)
Candiolo, Italy
Pratia MCM Krakow ( Site 1702)
Krakow, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1701)
Warsaw, Poland
Samsung Medical Center ( Site 0801)
Seoul, South Korea
Institut Català d'Oncologia (ICO) - Badalona ( Site 0904)
Badalona, Spain
Hospital Virgen de la Victoria ( Site 0905)
Málaga, Spain
Hospital Universitari Vall de Hebron ( Site 0903)
Barcelona, Spain
Hospital Universitario Gregorio Maranon ( Site 0902)
Madrid, Spain
Hospital Universitario de Salamanca ( Site 0906)
Salamanca, Spain
National Taiwan University Hospital ( Site 1001)
Taipei, Taiwan
Chang Gung Medical Foundation-Linkou Branch ( Site 1002)
Taoyuan, Taiwan
Hacettepe Universite Hastaneleri ( Site 1110)
Ankara, Turkey (Türkiye)
Sisli Florence Nightingale Hastanesi ( Site 1112)
Istanbul, Turkey (Türkiye)
Ondokuz Mayıs Universitesi ( Site 1113)
Samsun, Turkey (Türkiye)
Trial contact
Toll Free Number
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.